CLX's Productivity Drive: Likely to Aid Margins & Offset High Costs?

Clorox (CLX) is implementing productivity initiatives, including ERP upgrades and digital tools, aimed at streamlining operations and driving margin expansion; the company expects a 150 bps increase in gross margin for fiscal year 2025, which will partially offset rising costs from inflation and tariffs. These efforts are part of a broader trend among competitors like Colgate-Palmolive and Procter & Gamble, who are also focusing on productivity to counter inflationary pressures. Despite these initiatives, CLX shares have underperformed, declining approximately 23% year-to-date, and EPS estimates for fiscal 2026 indicate a potential decline of 5.4%.

Analysis

The Clorox Company (CLX) is actively pursuing significant productivity enhancements, including enterprise resource planning (ERP) upgrades and digital tool implementation, to streamline operations and bolster margins amidst a volatile economic environment. Management anticipates these efforts will contribute to a 150 basis point (bps) increase in gross margin for fiscal year 2025, partially mitigating pressures from cost inflation, trade promotional expenses, and tariffs. This strategy already shows traction, with the gross margin expanding 240 bps year-over-year in the third quarter of fiscal 2025, marking the tenth consecutive quarter of such expansion, attributed to cost savings and divestiture gains. However, these initiatives involve substantial investment, with fiscal 2025 adjusted EPS excluding an estimated 70 cents related to digital capabilities and productivity enhancements, and selling and administrative expenses projected to be 15-16% of net sales, reflecting a 150 bps impact from these strategic investments. This focus on productivity is mirrored by competitors like Colgate-Palmolive, Procter & Gamble, and Newell Brands, all aiming to counter inflationary pressures. Despite these operational improvements, CLX's shares have significantly underperformed, declining approximately 23% year-to-date compared to the industry's 0.7% dip. From a valuation perspective, CLX trades at a forward price-to-earnings ratio of 18.31X, below the industry average of 20.46X. While the Zacks Consensus Estimate for CLX’s EPS for fiscal 2025 indicates 14.9% year-over-year growth, fiscal 2026 forecasts suggest a 5.4% decline, and estimates for both fiscal years have seen downward revisions in the past 30 days.

Key Decisions for Investors

• Investors should weigh Clorox's demonstrated progress in margin expansion through productivity initiatives against its significant year-to-date stock underperformance and the recent downward revisions to fiscal 2025 and 2026 earnings per share estimates.
• The current valuation at a discount to the industry average may warrant consideration, but this should be balanced with the forecasted EPS decline in fiscal 2026 and the execution risks associated with ongoing strategic investments.
• Monitor upcoming financial reports for sustained gross margin improvements beyond fiscal 2025, the actual return on digital and productivity investments, and any updates to the fiscal 2026 outlook, which currently signals a contraction.
• Consider the intensely competitive environment where peers are also aggressively pursuing productivity gains, potentially impacting Clorox's ability to maintain or grow market share and pricing power despite its internal efforts.